Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)

CAPS Rating: 3 out of 5

A pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer.

Results 1 - 20 of 30 : 1 2 Next »

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 9/14/2012 9:58:09 AM : Outperform Start Price: $4.07 ASTX Score: +87.92

going up immediately, will surge when expected eu approval for AML on Dacogen by end of September. stay tuned

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 4/7/2012 3:43:23 PM : Outperform Start Price: $1.80 ASTX Score: +335.32

A wonder in their industry. A biotech with actual revenues and a deep pipeline.

Recs

0
Member Avatar Imhilion (26.26) Submitted: 2/12/2012 8:42:23 PM : Outperform Start Price: $2.06 ASTX Score: +273.10

Technical Indicators!

Recs

0
Member Avatar seattle1218 (< 20) Submitted: 1/27/2012 6:05:11 PM : Outperform Start Price: $2.66 ASTX Score: +174.95

Several drugs in the pipeline, will rise in value at least until it reaches the point of fda approval which is March 9, 1012. I may sell before that day.

Recs

0
Member Avatar niggyt (48.18) Submitted: 4/20/2011 3:48:59 PM : Outperform Start Price: $2.64 ASTX Score: +180.19

They have cash.

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 1/21/2011 2:56:52 PM : Outperform Start Price: $2.93 ASTX Score: +143.39

SuperGen is due.

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 11/12/2010 12:00:53 PM : Outperform Start Price: $2.69 ASTX Score: +159.19

Drugs and longshots that could get super real.

Recs

0
Member Avatar RickyMojo (21.57) Submitted: 4/8/2010 11:40:36 PM : Outperform Start Price: $3.20 ASTX Score: +107.12

Cure for cancer?

Recs

0
Member Avatar zackmax (23.75) Submitted: 3/11/2010 3:41:14 PM : Outperform Start Price: $3.25 ASTX Score: +97.95

ccest compte

Recs

0
Member Avatar craigt101 (90.95) Submitted: 11/25/2009 5:40:11 PM : Outperform Start Price: $2.74 ASTX Score: +140.37

Well heeled, financially...a comfortable moat...provides lots of room for R&D without feeling the pinch. Management appears to have built and strong model for developing cancer and related therapies that cover a broad spectrum of life-threatening diseases. I originally bought in at $2.22 and will give it several years. Who knows...maybe a buyout is down the line, as well.

Recs

0
Member Avatar libertybrewcity (< 20) Submitted: 11/2/2009 5:13:10 PM : Outperform Start Price: $2.37 ASTX Score: +176.76

lots of cash, pipeline with good potential

Recs

0
Member Avatar topsecret10 (< 20) Submitted: 10/13/2009 6:32:30 PM : Outperform Start Price: $2.56 ASTX Score: +158.48

Lots of Insider buying here..... SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer.
The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses.
The company is led by a seasoned management team with extensive experience in all aspects of the oncology pharmaceutical industry. TS

Recs

0
Member Avatar ramgee1 (< 20) Submitted: 7/29/2009 5:01:50 AM : Outperform Start Price: $2.75 ASTX Score: +114.55

They have significant cash and cash flow to enable the development of their pipeline of drug candidates. They are a significant buyout possibility.

Recs

0
Member Avatar realworld2 (< 20) Submitted: 7/24/2009 11:56:52 PM : Outperform Start Price: $2.88 ASTX Score: +100.48

great pipeline. bought at 2.01 with real money

Recs

0
Member Avatar Bullbuzz (< 20) Submitted: 1/8/2009 1:33:38 PM : Outperform Start Price: $2.13 ASTX Score: +185.72

Has some great research in the cancer field. Has become more financially focused. Products in pipeline very promising. Should take off from here.

Recs

0
Member Avatar ramgee (68.07) Submitted: 11/11/2008 5:31:43 PM : Outperform Start Price: $1.73 ASTX Score: +271.84

Ongoing revenue to operate with while new drugs are developed. Speculation with cash on board.

Recs

0
Member Avatar biovestor (< 20) Submitted: 6/28/2008 6:19:09 AM : Outperform Start Price: $2.20 ASTX Score: +234.12

A cancer biotech stock trading for near cash with zero debt with pending EORTC survival data due shortly for Dacogen likley to support EU marketing application by JNJ. Dacogen is already apporved in USA and SUPG has a robust, early-stage cancer piepline and discovery platform in place.

Recs

0
Member Avatar NWTOGME (< 20) Submitted: 5/30/2008 1:58:16 AM : Outperform Start Price: $2.48 ASTX Score: +203.56

At bottom price NO dept royalty income,pe low why not.

Recs

0
Member Avatar azballgofar (< 20) Submitted: 2/25/2008 1:38:12 PM : Outperform Start Price: $2.46 ASTX Score: +200.20

Has been looking kind of doggey but there are events to be disclosed.

Recs

0
Member Avatar abacusdude (97.78) Submitted: 12/22/2007 12:58:12 PM : Outperform Start Price: $3.99 ASTX Score: +80.92

According to Nasdaq:

1 - Underperform

3 - Hold

3 - Buy

The 12 month consensus is $10. Looks good to me!

Results 1 - 20 of 30 : 1 2 Next »

Featured Broker Partners


Advertisement